FDA Will Not Appeal Ruling Against LDT Regulation, Giving a Big Victory to Labs
The legal strategy of the ACLA—and some political luck—prevailed in the lawsuit against LDT oversight
The legal strategy of the ACLA—and some political luck—prevailed in the lawsuit against LDT oversight
A leaked budget document for the next fiscal year suggested non-user fee funding may be up slightly compared to recent years.
CAP and AMP officials weigh in on plans to push for a legislative- or CLIA-based approach to future LDT oversight
Marginal LDT scenarios could be where the FDA focuses on next, a lawyer notes
Judge rules that the FDA has ‘no authority’ to issue its rule governing laboratory-developed tests
Agency says it will continue to have authority to clear new lab tests and other COVID-19 products on an emergency basis even after the PHE ends.
At the end of 2022, the agency sent a new warning letter to Empowered for unauthorized distribution of COVID-19 test kits.
The agency recently announced subtle but significant changes to its policies governing review of new lab tests for COVID-19.
In a move to expand access to lab testing for monkeypox, HHS has authorized the FDA to issue EUAs for in vitro diagnostic tests for the virus.
Counterfeit COVID-19 tests are being illegally imported into the US and being distributed to unsuspecting consumers across the country.